Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema (bilateral)
ICD-10 E09.3513 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema (bilateral).
E09.3513 refers to diabetes mellitus that has been induced by drugs or chemicals, characterized by the presence of proliferative diabetic retinopathy (PDR) and bilateral macular edema. Drug-induced diabetes can occur due to various medications, including glucocorticoids, antipsychotics, and certain antiretrovirals. Proliferative diabetic retinopathy is a severe complication of diabetes where new, abnormal blood vessels grow on the retina, leading to potential vision loss. The presence of macular edema indicates fluid accumulation in the macula, the central part of the retina responsible for sharp vision. This condition requires careful management of blood glucose levels, often necessitating insulin therapy and regular monitoring of HbA1c levels to prevent further complications. The management of this condition is complex due to the interplay between the underlying diabetes, the effects of the inducing drug, and the complications arising from retinopathy and edema.
Detailed medication history, HbA1c levels, and management plans.
Patients presenting with new-onset diabetes after starting a new medication.
Ensure clear documentation of the drug responsible for diabetes onset.
Detailed retinal examination findings, imaging results, and treatment plans.
Patients with diabetes presenting for routine eye exams showing signs of retinopathy.
Document the severity and bilateral nature of retinopathy and edema.
Used for routine eye exams in patients with diabetes.
Document visual acuity, fundoscopic findings, and any treatment plans.
Ophthalmologists should ensure detailed documentation of retinopathy findings.
Medications such as glucocorticoids, certain antipsychotics, and some antiretrovirals are known to induce diabetes by affecting insulin secretion or action.